当前位置: 首页 >> 检索结果
1153. Atezolizumab in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial.
作者: Robert Haddad.;Jérôme Fayette.;Maria Teixeira.;Kumar Prabhash.;Ricard Mesia.;Andrzej Kawecki.;Arunee Dechaphunkul.;José Dinis.;Ye Guo.;Muneyuki Masuda.;Ching-Yun Hsieh.;Maria Grazia Ghi.;Claudia Vaz de Melo Sette.;Kevin Harrington.;Makoto Tahara.;Nabil F Saba.;Agnes Lau.;Tao Jiang.;Yibing Yan.;Marcus Ballinger.;Monika Kaul.;Christina Matheny.;Vaikunth Cuchelkar.;Deborah J Wong.
来源: JAMA. 2025年333卷18期1599-1607页
Treating locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) involves any combination of surgery, radiation, and chemotherapy, followed by routine monitoring for local recurrence or distant metastases. Given the poor patient outcomes, a significant unmet clinical need for improved treatment options remains.
1155. Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma: The DIPPER Randomized Clinical Trial.
作者: Ye-Lin Liang.;Xu Liu.;Liang-Fang Shen.;Guang-Yuan Hu.;Guo-Rong Zou.;Ning Zhang.;Chuan-Ben Chen.;Xiao-Zhong Chen.;Xiao-Dong Zhu.;Ya-Wei Yuan.;Kun-Yu Yang.;Feng Jin.;Wei-Han Hu.;Fang-Yun Xie.;Ying Huang.;Fei Han.;Ling-Long Tang.;Yan-Ping Mao.;Li-Xia Lu.;Rui Sun.;Yu-Xiang He.;Yang-Ying Zhou.;Guo-Xian Long.;Jie Tang.;Lu-Si Chen.;Jing-Feng Zong.;Ting Jin.;Ling Li.;Jie Lin.;Jing Huang.;Xiu-Yun Gong.;Guan-Qun Zhou.;Lei Chen.;Wen-Fei Li.;Yu-Pei Chen.;Cheng Xu.;Li Lin.;Shao-Hui Huang.;Sai-Wei Huang.;Ya-Qin Wang.;Cheng-Long Huang.;Hui-Xia Feng.;Min Hou.;Chun-Hua Chen.;Su-Fen Zheng.;Ying-Qing Li.;Shu-Bin Hong.;Yu-Sheng Jie.;Hao Li.;Jing-Ping Yun.;Sheng-Bing Zang.;Song-Ran Liu.;Qing-Guang Lin.;Hao-Jiang Li.;Li Tian.;Li-Zhi Liu.;Hong-Yun Zhao.;Ji-Bin Li.;Ai-Hua Lin.;Na Liu.;Yuan Zhang.;Rui Guo.;Jun Ma.;Ying Sun.
来源: JAMA. 2025年333卷18期1589-1598页
Approximately 20% to 30% of patients with locoregionally advanced nasopharyngeal carcinoma (NPC) experience disease relapse despite definitive chemoradiotherapy. The programmed cell death 1 (PD-1) blockade camrelizumab has demonstrated considerable value in recurrent or metastatic NPC, while its role in locoregionally advanced NPC is unclear.
1159. CNM-Au8 in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial.
作者: .;James D Berry.;Nicholas J Maragakis.;Eric A Macklin.;Lori B Chibnik.;Melanie Quintana.;Benjamin R Saville.;Michelle A Detry.;Matteo Vestrucci.;Joseph Marion.;Anna McGlothlin.;Elijah W Stommel.;Marianne Chase.;Lindsay Pothier.;Brittney A Harkey.;Hong Yu.;Alex Sherman.;Jeremy Shefner.;Meghan Hall.;Gale Kittle.;Suma Babu.;Jinsy Andrews.;Derek D'Agostino.;Eric Tustison.;Erica Scirocco.;Elisa Giacomelli.;Gustavo Alameda.;Eduardo Locatelli.;Doreen Ho.;Adam Quick.;Senda Ajroud-Driss.;Jonathan Katz.;Daragh Heitzman.;Stanley H Appel.;Sheetal Shroff.;Kevin J Felice.;Zachary Simmons.;Timothy Miller.;Nicholas Olney.;Michael D Weiss.;Stephen A Goutman.;Joseph Americo Fernandes.;Omar Jawdat.;Margaret Ayo Owegi.;Laura Foster.;Tuan Vu.;Hristelina Ilieva.;Daniel S Newman.;Ximena Arcila-Londono.;Carlayne Jackson.;Shafeeq Ladha.;Terry Heiman-Patterson.;James Caress.;Andrea Swenson.;Amanda Peltier.;Richard Lewis.;Dominic Fee.;Matthew Elliott.;Richard Bedlack.;Edward J Kasarskis.;Lauren Elman.;Jeffrey Rosenfeld.;David Walk.;Courtney E McIlduff.;Paul Twydell.;Eufrosina Young.;Kristin Johnson.;Kourosh Rezania.;Namita A Goyal.;Jeffrey A Cohen.;Michael Benatar.;Vovanti Jones.;Jonathan Glass.;Jaimin Shah.;Said R Beydoun.;James P Wymer.;Lindsay Zilliox.;Shakti Nayar.;Gary L Pattee.;Jennifer Martinez-Thompson.;Austin Rynders.;Jacob Evan.;Jeremy Evan.;Alan Hartford.;Marjan Sepassi.;Karen S Ho.;Robert Glanzman.;Benjamin Greenberg.;Michael T Hotchkin.;Sabrina Paganoni.;Merit E Cudkowicz.; .
来源: JAMA. 2025年333卷13期1138-49页
Bioenergetic failure has been proposed as a driver of amyotrophic lateral sclerosis (ALS). CNM-Au8 is a suspension of gold nanocrystals that catalyzes the conversion of nicotinamide adenine dinucleotide hydride into NAD+, resulting in an increase of cellular adenosine triphosphate production.
1160. Pridopidine in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial.
作者: .;Jeremy M Shefner.;Björn Oskarsson.;Eric A Macklin.;Lori B Chibnik.;Melanie Quintana.;Benjamin R Saville.;Michelle A Detry.;Matteo Vestrucci.;Joe Marion.;Anna McGlothlin.;Terry Heiman-Patterson.;Marianne Chase.;Lindsay Pothier.;Brittney A Harkey.;Hong Yu.;Alexander V Sherman.;Meghan Hall.;Gale Kittle.;James D Berry.;Suma Babu.;Jinsy Andrews.;Derek D'Agostino.;Eric Tustison.;Erica Scirocco.;Elisa Giacomelli.;Gustavo Alameda.;Eduardo Locatelli.;Doreen Ho.;Adam Quick.;Senda Ajroud-Driss.;Jonathan Katz.;Daragh Heitzman.;Stanley H Appel.;Sheetal Shroff.;Kevin Felice.;Nicholas J Maragakis.;Zachary Simmons.;Timothy M Miller.;Nicholas Olney.;Michael D Weiss.;Stephen A Goutman.;Joseph Americo Fernandes.;Omar Jawdat.;Margaret Ayo Owegi.;Laura A Foster.;Tuan Vu.;Hristelina Ilieva.;Daniel S Newman.;Ximena Arcila-Londono.;Carlayne E Jackson.;Shafeeq Ladha.;James B Caress.;Andrea Swenson.;Amanda Peltier.;Richard A Lewis.;Dominic Fee.;Matthew Elliott.;Richard Bedlack.;Edward J Kasarskis.;Lauren Elman.;Jeffrey Rosenfeld.;David Walk.;Courtney McIlduff.;Paul Twydell.;Eufrosina Young.;Kristin Johnson.;Kourosh Rezania.;Namita A Goyal.;Jeffrey A Cohen.;Michael Benatar.;Vovanti Jones.;Jaimin Shah.;Said R Beydoun.;James P Wymer.;Lindsay Zilliox.;Shakti Nayar.;Gary L Pattee.;Jennifer Martinez-Thompson.;Melanie L Leitner.;Kelly Chen.;Y Paul Goldberg.;Yael Cohen.;Michal Geva.;Michael R Hayden.;Sabrina Paganoni.;Merit E Cudkowicz.; .
来源: JAMA. 2025年333卷13期1128-37页
Amyotrophic lateral sclerosis (ALS) is a fatal disease. The sigma-1 (σ1) receptor emerged as a target for intervention.
|